文献速递基础与转化研究组学、生物样本库与精准医学医学人工智能与信息学

糖尿病早期视网膜神经变性的血浆蛋白质组特征:多队列研究

Plasma proteomic signatures of early retinal neurodegeneration in diabetes: A multi-cohort study.
PubMed 文献 · PLoS Med · 2026-06-02

该多队列前瞻性观察研究整合高通量血浆蛋白质组学与纵向OCT,在发现队列1492人中识别出71种与糖尿病视网膜神经变性(DRN)相关的血浆蛋白,并构建基于机器学习的Pro-DRN预测模型。模型在独立测试集中C-index达0.860,联合临床变量升至0.908,并在英国生物银行跨种族外部验证中重现核心蛋白信号。

要点

  • 71种血浆蛋白与DRN发生和进展相关,富集于炎症免疫招募、细胞外基质重塑和微血管稳态通路。
  • Pro-DRN模型在独立测试集C-index为0.860,联合临床变量升至0.908。
  • Pro-DRN已部署为交互式网络风险评估工具,支持早期DRN筛查与纵向监测。

核心结论

  • 基于蛋白质组学和机器学习的Pro-DRN系统可显著提升DRN早期风险分层,超越传统临床因素。

研究设计与样本

  • 多队列前瞻性观察研究,发现队列1492人(广州糖尿病眼病研究),其中1218人接受6年重复OCT随访。
  • DRN以年化OCT视网膜神经纤维层变薄率量化,多变量分析调整年龄、性别、吸烟、收缩压、HbA1c和糖尿病病程。
  • 采用8种机器学习算法(含XGBoost和LightGBM)构建Pro-DRN模型,并在英国生物银行(n=502,2006-2010年招募)进行跨种族外部验证。

主要发现

  • 鉴定出71种与DRN发生和进展相关的血浆蛋白,映射至炎症免疫招募、细胞外基质重塑和微血管稳态通路。
  • Pro-DRN在独立测试集C-index为0.860,联合临床变量后升至0.908。
  • 与6种传统模型相比,Pro-DRN改善判别能力(ΔC-index 0.137至0.159;均P<0.001)。
  • 在Hippisley模型中,C-index从0.739(95%CI [0.670, 0.808])升至0.898(95%CI [0.858, 0.937]),IDI 0.245(95%CI [0.177, 0.318]),NRI 0.452(95%CI [0.222, 0.673]),均P<0.001。
  • ACTA2、COL6A3和HSPG2是驱动模型性能最一致的蛋白。

关键数值与推荐

  • Pro-DRN改善重分类:IDI 0.212至0.245,NRI 0.226至0.452,均P<0.05。
  • Pro-DRN已部署为交互式网络风险评估工具,用于早期DRN筛查和纵向监测。
  • 英国生物银行外部验证重现核心蛋白信号和一致效应方向。

临床怎么用

  • Pro-DRN可作为基于血浆蛋白的DRN早期风险分层工具,辅助靶向筛查和及时神经保护干预。
  • 模型以网络工具形式部署,便于临床开展早期DRN筛查与纵向监测。

局限性

  • 主要方法学局限为单时间点蛋白质组评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Retinal neurodegeneration is an early and independent feature of diabetic retinal disease and has been proposed as a window into the systemic neural consequences of diabetes, yet accessible molecular biomarkers and individualized prediction tools remain scarce. We aimed to identify circulating plasma protein signatures of diabetic retinal neurodegeneration (DRN) and to translate them into a clinically usable risk prediction system. METHODS AND FINDINGS: In this multi-cohort prospective observational study, we integrated high-throughput plasma proteomics with longitudinal optical coherence tomography (OCT) in two independent populations. The discovery cohort comprised 1,492 participants had baseline plasma proteomics and OCT, and 1,218 were followed with repeated OCT over 6 years in Guangzhou Diabetic Eye Study (GDES). DRN was quantified by the annualized OCT-derived retinal nerve fiber layer thinning rate. In multivariable analyses adjusted for age, sex, smoking, systolic blood pressure, HbA1c, and diabetes duration, we identified 71 plasma proteins associated with development and progression of DRN. These proteins mapped onto pathways governing inflammatory immune recruitment, extracellular matrix remodeling, and microvascular homeostasis, providing a plausible biological basis for DRN. We developed a proteomics-based DRN model (Pro-DRN) using eight machine learning (ML) algorithms, including XGBoost and LightGBM. In the independent test set, Pro-DRN achieved a C-index of 0.860, rising to 0.908 when integrated with clinical variables. Compared with six conventional models, Pro-DRN improved discrimination (ΔC-index 0.137 to 0.159; all P < 0.001), reclassification (IDI 0.212 to 0.245; NRI 0.226 to 0.452; all P < 0.05). In the Hippisley model, the C-index increased from 0.739 (95% CI [0.670, 0.808]) to 0.898 (95% CI [0.858, 0.937]), with IDI 0.245 (95% CI [0.177, 0.318]), NRI 0.452 (95% CI [0.222, 0.673]) (both P < 0.001), and higher net benefit. The proteins most consistently driving model performance included ACTA2, COL6A3, and HSPG2. For clinical translation, we deployed the locked model as an interactive, web-based risk-assessment tool to support early DRN screening and longitudinal monitoring. Cross-ethnic external validation in UK Biobank (n = 502; recruited 2006-2010) reproduced core protein signals and consistent effect directions, confirming robustness across populations. Principal methodological limitation lies in single time point proteomic assessment. CONCLUSION: In this multi-cohort study, we present a proteomics- and ML-based precision prediction system for DRN. Pro-DRN substantially enhanced early risk stratification beyond conventional clinical factors and may support targeted screening and timely neuroprotective interventions, advancing molecularly guided strategies for diabetic eye disease prevention.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Li H, Zhu Z, Yang S, et al. Plasma proteomic signatures of early retinal neurodegeneration in diabetes: A multi-cohort study. PLoS Med. 2026. PMID: 42228639. doi:10.1371/journal.pmed.1004868

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。